Ancestim

Ancestim
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	s.c. injection only, premedication with H1 and H2 antihistamines and beta-receptor agonists for bronchodilation
ATC code	L03AA12 (WHO) ;
Pharmacokinetic data
Elimination half-life	2.5 h
Excretion	renal: 90%
Identifiers
CAS Number	163545-26-4 ;
ChemSpider	none;
UNII	PYB4Q6JG41;
KEGG	D02937 ;
	(what is this?) (verify)

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Ancestim is a recombinant methionyl human stem cell factor, branded by Amgen as StemGen. It was developed by Amgen and sold to Biovitrium, now Swedish Orphan Biovitrum, in December, 2008.^[1]

It is a 166 amino acid protein produced by E. coli bacteria into which a gene has been inserted for soluble human stem cell factor.^[2] It has a monomeric molecular weight of approximately 18,500 daltons and normally exists as a noncovalently associated dimer. The protein has an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal methionine retained after expression in E. coli. Because Ancestim is produced in E. coli, it is nonglycosylated. Ancestim is supplied as a sterile, white, preservative-free, lyophilised powder for reconstitution and administration as a subcutaneous (SC) injection and is indicated for use in combination with filgrastim for mobilizing peripheral hematopoietic stem cells for later transplantation in certain cancer patients.^[3]

References

^ Amgen press office. Biovitrum Closes Product Acquisition Deal with Amgen Archived July 3, 2012, at the Wayback Machine
^ da Silva MG, Pimentel P, Carvalhais A, et al. (2004). "Ancestim (recombinant human stem cell factor, SCF) in association with filgrastim does not enhance chemotherapy and/or growth factor-induced peripheral blood progenitor cell (PBPC) mobilization in patients with a prior insufficient PBPC collection". Bone Marrow Transplant. 34 (8): 683–91. doi:10.1038/sj.bmt.1704602. PMID 15322567. S2CID 21830065.
^ "Sobi's StemGen page". Archived from the original on 2016-07-29. Retrieved 2013-12-30.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[BiovitriumDeal-1] Amgen press office. Biovitrum Closes Product Acquisition Deal with Amgen Archived July 3, 2012, at the Wayback Machine

[pmid15322567-2] Silva MG, Pimentel P, Carvalhais A, et al. (2004). "Ancestim (recombinant human stem cell factor, SCF) in association with filgrastim does not enhance chemotherapy and/or growth factor-induced peripheral blood progenitor cell (PBPC) mobilization in patients with a prior insufficient PBPC collection". Bone Marrow Transplant. 34 (8): 683–91. doi:10.1038/sj.bmt.1704602. PMID 15322567. S2CID 21830065.

[3] "Sobi's StemGen page". Archived from the original on 2016-07-29. Retrieved 2013-12-30.

[1]

[2]

[3]